| Literature DB >> 29534732 |
Jasper M Smit1,2, Reinder Raadsen3,4, Michiel J Blans5, Manfred Petjak6, Peter M Van de Ven7, Pieter R Tuinman3,4.
Abstract
BACKGROUND: Insertion of a central venous catheter (CVC) is common practice in critical care medicine. Complications arising from CVC placement are mostly due to a pneumothorax or malposition. Correct position is currently confirmed by chest x-ray, while ultrasonography might be a more suitable option. We performed a meta-analysis of the available studies with the primary aim of synthesizing information regarding detection of CVC-related complications and misplacement using ultrasound (US).Entities:
Keywords: CVC malposition; Central venous catheter; Chest x-ray; Iatrogenic complications; Meta-analysis; Pneumothorax; Ultrasound
Mesh:
Year: 2018 PMID: 29534732 PMCID: PMC5851097 DOI: 10.1186/s13054-018-1989-x
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1PRISMA flow diagram of search strategy and study selection. Depicted in the flow diagram are the number of identified records, the number of screened records, the number of articles assessed for eligibility with reasons for exclusion, and the number of studies included in the qualitative and quantitative syntheses
Study characteristics
| Author (year) | Study design (period)1 | Setting (country) | Patients (CVCs), | Ultrasoundprotocol | Reference standard | Primary outcome (secondary outcome) | Performing operators (experienced operators), |
|---|---|---|---|---|---|---|---|
| Killu et al. (2010) [ | Prospective pilot study | Surgical ICU (United States) | 5 (5) | Supraclavicular ultrasounda | CXR | Malposition (time advancement guidewire) | 1 (1) |
| Kim et al. (2015) [ | Prospective pilot study (Jul 2012–Oct 2012) | Operating theatres (Germany) | 51 (51) | Supraclavicular ultrasoundb | CXR/TEE | Malposition (time until confirmation) | 2 (2) |
| Kim et al. (2016) [ | Prospective pilot study(Jun 2014–Aug 2014) | Operating theatres (Germany) | 20 (20) | Supraclavicular ultrasoundb | CXR | Malposition (time advancement guidewire) | 1 (1) |
| Baviskar et al. (2015) [ | Prospective study (Apr 2013–Jan 2014) | Surgical ICU (India) | 25 (25) | TTE and CEUSa | CXR | Time until confirmation (malposition) | 1 + (1+)3 experienced staff |
| Cortellaro et al. (2014) [ | Prospective study | Emergency department (Italy) | 71 (71) | TTE and CEUSa | CXR | Malposition (time until confirmation) | 3 (2) |
| Duran-Gehring et al. (2015) [ | Prospective study (Dec 2012–Nov 2013) | Emergency department (United States) | 50 (50) | TTE and CEUSa | CXR | Time until confirmation (malposition, pneumothorax) | 2 (2) |
| Gekle et al. (2015) [ | Prospective study (Dec 2012–Mar 2014) | Emergency department (United States) | 81 (81) | TTE and CEUSa | CXR | Malposition, pneumothorax (time until confirmation) | Unclear |
| Kamalipour et al. (2016) [ | Prospective study (Aug 2013–Jan 2014) | Operating theatres (Iran) | 116 (116) | TTE and CEUSa | CXR | Malposition | 1 (1) |
| Lanza et al. (2006) [ | Prospective study (Nov 2004–Sep 2005) | Pediatric ICU (Italy) | 107 (107) | TTE and CEUSa | CXR | Malposition, pneumothorax | 1 (1) |
| Salimi et al.2 (2015) [ | Prospective study | Nephrology department (Iran) | 82 (82) | TTE and CEUSa | CXR | Malposition, pneumothorax | 1 (1) |
| Santarsia et al. (2000) [ | Prospective study | Nephrology department (Italy) | 158 (158) | TTE and CEUSa | CXR | Malposition | Unclear |
| Weekes et al. (2014) [ | Prospective study (Jan 2013–Apr 2013) | Emergency department and ICU | 147 (152) | TTE and CEUSa | CXR | Malposition | 5 (5) |
| Weekes et al. (2016) [ | Prospective study (Nov 2013–Mar 2015) | Emergency department and ICU | 156 (156) | TTE and CEUSa | CXR | Malposition, pneumothorax (time until confirmation) | Unclear, by or under supervision of study investigator |
| Wen et al. (2014) [ | Retrospective study (Jun 2011–Jul 2012) | Nephrology department (Germany) | 202 (219) | TTE and CEUSa | CXR | Malposition (time until confirmation) | 2 + (2+)3 |
| Alonso-Quintela et al. (2015) [ | Prospective study (Jan 2012–Jan 2014) | Pediatric ICU (Spain) | 40 (51) | Vascular ultrasound and TTEa | CXR | Malposition (time until confirmation) | 1 (1) |
| Maury et al. (2001) [ | Prospective study (Mar 1999–Sep 1999) | ICU (France) | 81 (85) | Vascular ultrasound and TTEa | CXR | Malposition, pneumothorax (time until confirmation) | 3 (0) |
| Miccini et al. (2016) [ | Prospective study (Jan 2012–Dec 2014) | Operating theatres (Italy) | 302 (302) | Vascular ultrasound and TTEa | IF/CXR | Malposition, pneumothorax | 2 (2) |
| Park et al. (2014) [ | Prospective study | Pediatric ICU (United States) | 108 (108) | Vascular ultrasound and TTEa | CXR | Malposition (insertion depth CVC) | 3 (3) |
| Arellano et al. (2014) [ | Prospective study | Operating theatres (Canada) | 100 (100) | Vascular ultrasound and TTEb | TEE | Malposition | 4 (2) |
| Bedel et al. (2013) [ | Prospective study (Jan 2010–Nov 2010) | ICU (France) | 98 (101) | Vascular ultrasound and TTEb | CXR | Malposition (pneumothorax, time until confirmation) | 1 (1) |
| Blans et al. (2016) [ | Prospective study (Jan 2015–Sep 2015) | ICU (The Netherlands) | 53 (53) | Vascular ultrasound, TTE and CEUSa | CXR | Malposition, pneumothorax (time until confirmation) | 2 (2) |
| Matsushima and Frankel (2010) [ | Prospective study (Nov 2004–Sep 2005) | Surgical ICU (United States) | 69 (83) | Vascular ultrasound, TTE and CEUSa | CXR | Malposition, pneumothorax (time until confirmation) | 1 (0) |
| Meggiolaro et al. (2015) [ | Prospective study (Jan 2013–Sep 2013) | Operating theatres (Italy) | 105 (105) | Vascular ultrasound, TTE and CEUSa | CXR | Malposition, pneumothorax (timing bubble test, time until confirmation) | 1 (1) |
| Vezzani et al. (2010) [ | Prospective study (Apr 2008–Aug 2008) | ICU (Italy) | 111 (111) | Vascular ultrasound, TTE and CEUSa | CXR | Malposition, pneumothorax (time until confirmation, cost analysis) | 1 (1) |
| Zanobetti et al. (2013) [ | Prospective study (Jan 2009–Dec 2011) | Emergency department (Italy) | 210 (210) | Vascular ultrasound, TTE and CEUSa | CXR | Malposition, pneumothorax (time until confirmation) | 4 + (4+)3 |
CEUS contrast enhanced ultrasound, CVC central venous catheter, CXR chest x-ray, ICU intensive care unit, IF intra-fluoroscopy, TEE transesophageal echocardiography, TTE transthoracic echocardiography
aThe CVC is primarily visualized
bThe advancement of the guidewire is primarily visualized
1All studies were observational in design
2Accuracy CXR investigated; TTE used as reference standard
3Possible more than described amount of operators
Fig. 2Deek’s funnel plot asymmetry test for all 25 studies. The risk of bias when all 25 studies are included in Deek’s funnel plot asymmetry test (p = 0.91). ESS effective sample size
Fig. 3Deek’s funnel plot asymmetry test for 18 studies in which both specificity and sensitivity could be estimated. The risk of bias when only the 18 studies are included in Deek’s funnel plot asymmetry test for which both sensitivity and specificity could be estimated (p = 0.37). ESS effective sample size
Outcomes regarding feasibility, prevalence, accuracy parameters, and time to measurement of included studies
| Study | Feasibility | Prevalence of pneumothorax (%) | Prevalence of malposition (%) | Specificity (95% CI)1 | Sensitivity (95% CI)2 | Mean time for US (min) (±SD)4 [IQR] | Mean time for CXR performance (min) (±SD)4 [IQR] | Mean time for CXR interpretation (min) (±SD)4 [IQR] |
|---|---|---|---|---|---|---|---|---|
| Killu et al. (2010) [ | 100% | – | 0% | 100.0 (47.8–100) | – | 4.2 | – | – |
| Kim et al. (2015) [ | 92% | – | 0% | 100 (92.0–100) | – | 11 (0.72) | 111 (31) | – |
| Kim et al. (2016) [ | 100% | – | 0% | 100 (81.5–100) | – | – | – | – |
| Baviskar et al. (2015) [ | 100% | – | 0% | 100 (86.3–100) | – | 0.75 (0.25) | – | – |
| Cortellaro et al. (2014) [ | 100% | – | 8.4% | 98.5 (91.7–100) | 33.3 (4.3–77.7) | 4 (1) | – | 288 (216) |
| Duran-Gehring et al. (2015) [ | 92% | 4.3% | 6.5% | 100 (91.8–100) | 33.3 (0.8–90.6) | 5 (0.8) | 28.2 (11.3) | 299 (90.5) |
| Gekle et al. (2015) [ | 100% | 0% | 0% | 100 (94.7–100) | – | 8.80 (1.34) | 45.78 (8.75) | |
| Kamalipour et al. (2016) [ | 89.7% | – | 15.4% | 97.7 (92.0–99.7) | 68.8 (41.0–89.0) | – | – | – |
| Lanza et al. (2006) [ | 100% | 0.9% | 11.2% | 100 (96.2–100) | 83.3 (51.0–97.7) | – | – | – |
| Salimi et al.* (2015) [ | 100% | – | 30.5% | 91.2 (80.7–97.1) | 28.0 (12.1–49.4) | – | – | – |
| Santarsia et al. (2000) [ | 100% | – | 1.9% | 100 (93.3–100) | 100 (2.5–100) | – | – | – |
| Weekes et al. (2014) [ | 96.6% | – | 2.7% | 100 (97.5–100) | 75.0 (19.4–99.4) | – | – | – |
| Weekes et al. (2016) [ | 97.4% | – | 2.6% | 100 (97.5–100) | 75.0 (19.4–99.4) | 1.1 (0.7) | 20 (30) | – |
| Wen et al. (2014) [ | 100% | – | 0.9% | 100 (98.3–100) | 100 (15.8–100) | 3.2 (1.1) | 28.3 (25.7) | – |
| Alonso-Quintela et al. (2015) [ | 100% | – | 11.8% | 95.6 (84.9–99.5) | 100 (54.1–100) | 2.23 (1.06) | – | 22.96 (20.43) |
| Maury et al. (2001) [ | 98.8% | 1.2% | 10.7% | 100 (95.2–100) | 100 (66.4–100) | 6.8 (3.5) | 80.3 (66.7) | – |
| Miccini et al. (2016) [ | 100% | 1.0% | 1.3% | 100 (98.8–100) | 100 (39.8–100) | – | – | – |
| Park et al. (2014) [ | 96.2% | – | 0% | 100 (96.4–100) | – | – | – | – |
| Arellano et al. (2014) [ | 94% | – | 0% | 96.8 (91.0–99.3) | – | – | – | – |
| Bedel et al. (2013) [ | 97% | 0% | 6.2% | 100 (96.0–100) | 83.3 (35.9–99.6) | 1.76 (1.3) | 49 (31) | 103 (81) |
| Blans et al. (2016) [ | 98.1% | 0% | 5.8% | 98.0 (89.4–99.9) | 0 (0–70.8) | – | – | 24.5 [18.1–45.3] |
| Matsushima and Frankel (2010) [ | 71% | 0% | 16.9% | 98.0 (89.4–99.9) | 50.0 (18.7–81.3) | 10.8 | – | 75.3 |
| Meggiolaro et al. (2015) [ | 100% | 0% | 13.3% | 100 (96.0–100) | 64.3 (35.1–87.2) | 5.0 [5.0-10.0] | – | 67.0 [42.0–84.0] |
| Vezzani et al. (2010) [ | 89.2% | 1.8% | 28.3% | 95.8 (88.1–99.1) | 92.9 (76.5–99.1) | 10 (5) | 83 (79) | – |
| Zanobetti et al. (2013) [ | 100% | 2.0% | 4.4% | 100 (98.1–100) | 55.6 (21.2–86.3) | 5 (3) | – | 65 (74) |
| Pooled (patients, | (patients, | (patients, | (patients, | (patients, | (patients, | |||
| All studies (2548) | 96.8% | 1.1% | 6.8% | 98.4 (97.8–99.5) | 68.2 (54.4–79.4) | 2.83 (95% CI: 2.77–2.89) | 34.7 (95% CI: 32.6–36.7) | 46.3 (95% CI: 44.4–48.2) |
| Supraclavicular ultrasound (76) | 94.6% | – | 0% | 100 (94.4–100)3 | – | |||
| TTE and CEUS (1195) | 97.7% | 1.4% | 6.8% | 98.9 (96.1–99.7) | 68.7 (61.7–96.4) | |||
| Vascular ultrasound and TTE (729) | 98.1% | 0.8% | 3.4% | 99.0 (96.5–99.7) | 96.1 (79.7–99.4) | |||
| Vascular ultrasound, TTE and CEUS (548) | 93.3% | 1.4% | 12.3% | 98.6 (96.1–99.5) | 56.2 (32.8–77.1) |
CEUS contrast enhance ultrasound, CI confidence interval, CXR chest x-ray, IQR interquartile range, SD standard deviation, TTE transthoracic echocardiography, US ultrasound
*Accuracy CXR investigated; TTE used as reference standard
1One-sided 97.5% confidence interval in case specificity is estimated to be 100%
2One-sided 97.5% confidence interval in case sensitivity is estimated to be 100%
3Exact confidence intervals (not taking into account between-study differences); GEE model not estimable as all controls were correctly identified
4Values shown as mean (SD) or median [IQR]
Fig. 4Forest plot of the specificity and sensitivity of ultrasound for detection of CVC-related complications. The pooled specificity and sensitivity as well as the specificity and sensitivity for each study individually with their respective confidence interval (CI). Studies showed significant statistical heterogeneity; for specificity, I2 = 83.3 (95% CI: 64.6–86.7) and, for sensitivity, I2 = 75.5 (95% CI: 77.1–90.4)
Results of subgroup analysis
| Study | Ultrasound protocol | Specificity1 (95% CI) | Sensitivity2 (95% CI) |
|---|---|---|---|
| All studies (pooled) | |||
| Intra-atrial | 97.4 (94.8–98.7) | 73.5 (57.2–85.3) | |
| Extra-atrial | 100.0 (98.1–100.0) | 55.6 (21.2–86.3) | |
| Total | 98.6 (97.2–99.3) | 65.4 (50.7–77.6) | |
| TTE and CEUS | |||
| Cortellaro [ | |||
| Intra-atrial | 98.6 (92.2–100.0) | 50.0 (1.2–98.7) | |
| Extra-atrial | 100.0 (94.6–100.0) | 25.0 (0.6–80.6) | |
| Total | 98.5 (91.7–100.0) | 33.3 (4.3–77.7) | |
| Duran-Gehring [ | |||
| Intra-atrial | 100.0 (92.3–100.0) | –4 | |
| Extra-atrial | 100.0 (91.8–100.0) | 33.3 (0.8–90.6) | |
| Total | 100.0 (91.8–100.0) | 33.3 (0.8–90.6) | |
| Kamalipour [ | |||
| Intra-atrial | 97.8 (92.2–99.7) | 78.6 (49.2–95.3) | |
| Extra-atrial | 100.0 (96.4–100.0) | 0.0 (0.0–84.2) | |
| Total | 97.7 (92.0–99.7) | 68.8 (41.3–89.0) | |
| Lanza [ | |||
| Intra-atrial | 99.0 (94.6–100.0) | 71.4 (29.0–96.3) | |
| Extra-atrial | 100.0 (96.4–100.0) | 80.0 (28.4–99.5) | |
| Total | 98.9 (94.3–100.0) | 75.0 (42.8–94.5) | |
| Weekes [ | |||
| Intra-atrial | 100.0 (97.6–100.0) | –4 | |
| Extra-atrial | 100.0 (97.5–100.0) | 75.0 (19.4–99.4) | |
| Total | 100.0 (97.5–100.0) | 75.0 (19.4–99.4) | |
| Vascular ultrasound and TTE | |||
| Alonso-Quintela [ | |||
| Intra-atrial | 94.0 (83.4–98.7) | 100.0 (2.5–100.0) | |
| Extra-atrial | 100.0 (92.7–100.0) | 100.0 (15.8–100.0) | |
| Total | 93.8 (82.8–98.7) | 100.0 (29.2–100.0) | |
| Maury [ | |||
| Intra-atrial | 100.0 (95.4–100.0) | 100.0 (47.8–100.0) | |
| Extra-atrial | 100.0 (95.5–100.0) | 100.0 (39.8–100.0) | |
| Total | 100.0 (95.2–100.0) | 100.0 (66.4–100.0) | |
| Vascular ultrasound, TTE and CEUS | |||
| Blans [ | |||
| Intra-atrial | 100.0 (93.2–100.0) | 0.0 (0.0–70.8) | |
| Extra-atrial | 98.0 (89.6–100.0) | 0.0 (0.0–84.2) | |
| Total | 98.0 (89.4–99.9) | 0.0 (0.0–70.8) | |
| Matsushima [ | |||
| Intra-atrial | 98.2 (90.6–100.0) | 50.0 (1.3–98.7) | |
| Extra-atrial | 100.0 (93.2–100.0) | 50.0 (15.7–84.3) | |
| Total | 98.0 (89.4–99.9) | 50.0 (18.7–81.3) | |
| Meggiolaro3 [ | |||
| Intra-atrial | 95.8 (88.3–99.1) | 48.5 (30.8–66.5) | |
| Extra-atrial | 100.0 (96.0–100.0) | 64.3 (35.1–87.2) | |
| Total | 100.0 (96.0–100.0) | 64.3 (35.1–87.2) | |
| Vezzani [ | |||
| Intra-atrial | 96.0 (88.8–99.2) | 91.7 (73.0–99.0) | |
| Extra-atrial | 100.0 (96.2–100.0) | 100.0 (39.8–100.0) | |
| Total | 95.8 (88.1–99.1) | 92.9 (76.5–99.1) | |
| Zanobetti3 [ | |||
| Intra-atrial | 89.2 (81.5–94.5) | 94.2 (87.9–97.9) | |
| Extra-atrial | 100.0 (98.1–100.0) | 55.6 (21.2–86.3) | |
| Total | 100.0 (98.1–100.0) | 55.6 (21.2–86.3) | |
CEUS contrast enhance ultrasound, TTE transthoracic echocardiography
1One-sided 97.5% confidence interval (CI) in case specificity is estimated to be 100%
2One-sided 97.5% confidence interval in case sensitivity is estimated to be 100%
3Intra-atrial tip position was reported but was not considered to be a malposition
4No intra-atrial misplacements were detected
Fig. 5Forest plot for the specificity and sensitivity of ultrasound for detection of CVC-related complications distinguishing between intra- and extra-atrial malposition. The pooled specificity and sensitivity for intra- and extra-atrial malposition, and the specificity and sensitivity for each study individually. CI confidence interval
Quality assessment of included studies
*Accuracy CXR investigated; TTE used as reference standard
Orange is unclear risk of bias or applicability concern. Green is low risk of bias or applicability concern, and red is high risk of bias or applicability concern